HC Wainwright Reiterates Buy Rating on Cytokinetics, Keeps $140 Target
HC Wainwright reiterated its Buy rating on Cytokinetics and maintained a $140 price target. The target implies 126.0% upside from the Oct. 16 close of $61.95.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.